Figure 1. The anticipated work flow of individualized cancer treatment based on the unique molecular prolife of a patient.

For a given patient, the normal genome and tumor genome is sequenced by using next-generation sequencing. The genetic information is analyzed, validated, and clinically interpreted by a panel of multidisciplinary experts. A personalized treatment regimen is designed based on the unique genetics of the tumor and the patient's normal genome. In addition, the patient's family may benefit from knowing the risk of hereditary cancer and taking appropriate intervention. WGS, whole genome sequencing; WES, whole exome sequencing.